RedHill Biopharma Ltd.
RHB-204
Crohn's disease
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for RHB-204 in Crohn's disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“A planned Phase 2 study of RHB-204 in CD is expected to be the first clinical study in a specifically defined MAP-positive CD patient population.”